Oncology clinical trials are widely recognised as being amongst the
most complex trials to design, set up, and deliver. Whilst there is
good progress in finding optimal and durable treatment solutions,
the implementation of the enhanced understanding of molecular
pathology adds an additional layer to clinical trial operational
complexity, affirms Jozsef Palatka, MD, Vice President of Clinical
Development of Oncology, INC Research. The demand to find
treatment responses for various cancer indications is high, the
research is intensive, and the number of sophisticated clinical trials
is great.